Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 739

1.

Successful Treatment of Delayed Methotrexate Clearance using Glucarpidase Dosed on Ideal Body Weight in Obese Patients.

Krüger C, Engel N, Reinert J, Alsdorf W, Fiedler W, Dierlamm J, Bokemeyer C, Langebrake C.

Pharmacotherapy. 2020 Apr 2. doi: 10.1002/phar.2390. [Epub ahead of print]

PMID:
32239519
2.

Polyphenolic Compounds from Lespedeza Bicolor Root Bark Inhibit Progression of Human Prostate Cancer Cells via Induction of Apoptosis and Cell Cycle Arrest.

Dyshlovoy SA, Tarbeeva D, Fedoreyev S, Busenbender T, Kaune M, Veselova M, Kalinovskiy A, Hauschild J, Grigorchuk V, Kim N, Bokemeyer C, Graefen M, Gorovoy P, von Amsberg G.

Biomolecules. 2020 Mar 14;10(3). pii: E451. doi: 10.3390/biom10030451.

3.

Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma.

Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S.

Leukemia. 2020 Mar 3. doi: 10.1038/s41375-020-0781-5. [Epub ahead of print]

PMID:
32127637
4.

Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells.

Böckelmann L, Starzonek C, Niehoff AC, Karst U, Thomale J, Schlüter H, Bokemeyer C, Aigner A, Schumacher U.

Histochem Cell Biol. 2020 Mar 3. doi: 10.1007/s00418-020-01857-x. [Epub ahead of print]

PMID:
32125512
5.

Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer.

Hennigs JK, Minner S, Tennstedt P, Löser R, Huland H, Klose H, Graefen M, Schlomm T, Sauter G, Bokemeyer C, Honecker F.

Sci Rep. 2020 Feb 24;10(1):3250. doi: 10.1038/s41598-020-60064-9.

6.

Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling.

Tintelnot J, Metz S, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Kriegs M, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M.

Front Oncol. 2020 Jan 21;9:1559. doi: 10.3389/fonc.2019.01559. eCollection 2019.

7.

Impact, challenges and limits of inpatient palliative care consultations - perspectives of requesting and conducting physicians.

Coym A, Oechsle K, Kanitz A, Puls N, Blum D, Bokemeyer C, Ullrich A.

BMC Health Serv Res. 2020 Feb 4;20(1):86. doi: 10.1186/s12913-020-4936-x.

8.

Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma.

Schieferdecker A, Hörber S, Ums M, Besemer B, Bokemeyer C, Peter A, Weisel K.

Blood Cancer J. 2020 Jan 9;10(1):2. doi: 10.1038/s41408-019-0267-8.

9.

Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review.

Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub LA, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen CF, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D, Dirksen U, Sander A, Köhler M, Habermann JK, Bokemeyer C, Stein A.

BMC Cancer. 2020 Jan 6;20(1):16. doi: 10.1186/s12885-019-6492-5.

10.

Implementation analysis of patient reported outcomes (PROs) in oncological routine care: an observational study protocol.

Görlach MG, Schrage T, Bokemeyer C, Kröger N, Müller V, Petersen C, Betz CS, Krüll A, Schulz H, Bleich C.

Health Qual Life Outcomes. 2020 Jan 2;18(1):3. doi: 10.1186/s12955-019-1262-2.

11.

Challenges Faced by Prehospital Emergency Physicians Providing Emergency Care to Patients with Advanced Incurable Diseases.

Kamphausen A, Roese H, Oechsle K, Issleib M, Zöllner C, Bokemeyer C, Ullrich A.

Emerg Med Int. 2019 Nov 26;2019:3456471. doi: 10.1155/2019/3456471. eCollection 2019.

12.

Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.

Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Hentrich M, Wheater M, Langberg CW, Ståhl O, Fankhauser CD, Hamid AA, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen S; Global Germ-Cell Cancer Group.

J Clin Oncol. 2019 Dec 26:JCO1901876. doi: 10.1200/JCO.19.01876. [Epub ahead of print]

PMID:
31877087
13.

Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.

Oing C, Hentrich M, Lorch A, Gläser D, Rumpold H, Ochsenreither S, Richter S, Dieing A, Zschäbitz S, Pereira RR, Bokemeyer C, Seidel C.

J Cancer Res Clin Oncol. 2020 Feb;146(2):449-455. doi: 10.1007/s00432-019-03071-2. Epub 2019 Dec 14.

PMID:
31838576
14.

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.

Stamm H, Oliveira-Ferrer L, Grossjohann EM, Muschhammer J, Thaden V, Brauneck F, Kischel R, Müller V, Bokemeyer C, Fiedler W, Wellbrock J.

Oncoimmunology. 2019 Oct 12;8(12):e1674605. doi: 10.1080/2162402X.2019.1674605. eCollection 2019.

PMID:
31741778
15.

Psychological burden in family caregivers of patients with advanced cancer at initiation of specialist inpatient palliative care.

Oechsle K, Ullrich A, Marx G, Benze G, Heine J, Dickel LM, Zhang Y, Wowretzko F, Wendt KN, Nauck F, Bokemeyer C, Bergelt C.

BMC Palliat Care. 2019 Nov 18;18(1):102. doi: 10.1186/s12904-019-0469-7.

16.

The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia.

Velthaus A, Cornils K, Hennigs JK, Grüb S, Stamm H, Wicklein D, Bokemeyer C, Heuser M, Windhorst S, Fiedler W, Wellbrock J.

Cancers (Basel). 2019 Oct 26;11(11). pii: E1663. doi: 10.3390/cancers11111663.

17.

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).

Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC, Bedard PL.

Cancer Med. 2020 Jan;9(1):116-124. doi: 10.1002/cam4.2674. Epub 2019 Nov 12.

18.

Rationale and Design of the Hamburg City Health Study.

Jagodzinski A, Johansen C, Koch-Gromus U, Aarabi G, Adam G, Anders S, Augustin M, der Kellen RB, Beikler T, Behrendt CA, Betz CS, Bokemeyer C, Borof K, Briken P, Busch CJ, Büchel C, Brassen S, Debus ES, Eggers L, Fiehler J, Gallinat J, Gellißen S, Gerloff C, Girdauskas E, Gosau M, Graefen M, Härter M, Harth V, Heidemann C, Heydecke G, Huber TB, Hussein Y, Kampf MO, von dem Knesebeck O, Konnopka A, König HH, Kromer R, Kubisch C, Kühn S, Loges S, Löwe B, Lund G, Meyer C, Nagel L, Nienhaus A, Pantel K, Petersen E, Püschel K, Reichenspurner H, Sauter G, Scherer M, Scherschel K, Schiffner U, Schnabel RB, Schulz H, Smeets R, Sokalskis V, Spitzer MS, Terschüren C, Thederan I, Thoma T, Thomalla G, Waschki B, Wegscheider K, Wenzel JP, Wiese S, Zyriax BC, Zeller T, Blankenberg S.

Eur J Epidemiol. 2020 Feb;35(2):169-181. doi: 10.1007/s10654-019-00577-4. Epub 2019 Nov 8.

19.

Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-Naphthoquinones.

Dyshlovoy SA, Pelageev DN, Hauschild J, Borisova KL, Kaune M, Krisp C, Venz S, Sabutskii YE, Khmelevskaya EA, Busenbender T, Denisenko VA, Pokhilo ND, Atopkina LN, Graefen M, Schlüter H, Stonik VA, Bokemeyer C, Anufriev VP, von Amsberg G.

Cancers (Basel). 2019 Oct 30;11(11). pii: E1690. doi: 10.3390/cancers11111690.

20.

Prevalence and Predictors of Distress, Anxiety, Depression, and Quality of Life in Bereaved Family Caregivers of Patients With Advanced Cancer.

Oechsle K, Ullrich A, Marx G, Benze G, Wowretzko F, Zhang Y, Dickel LM, Heine J, Wendt KN, Nauck F, Bokemeyer C, Bergelt C.

Am J Hosp Palliat Care. 2020 Mar;37(3):201-213. doi: 10.1177/1049909119872755. Epub 2019 Oct 9.

PMID:
31596115
21.

DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma.

Mazdak M, Tezval H, Callauch JC, Dubrowinskaja N, Peters I, Bokemeyer C, Hennenlotter J, Stenzl A, Kuczyk MA, Serth J.

Oncol Rep. 2019 Nov;42(5):2159-2168. doi: 10.3892/or.2019.7305. Epub 2019 Sep 9.

PMID:
31545450
22.

Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.

Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M; Aide et Recherche en Cancerologie Digestive Group.

JAMA Netw Open. 2019 Sep 4;2(9):e1911750. doi: 10.1001/jamanetworkopen.2019.11750.

23.

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers.

Rossi A, Voigtlaender M, Klose H, Schlüter H, Schön G, Loges S, Paolini M, Bokemeyer C, Reck M, Tarro G, Binder M.

J Oncol. 2019 Aug 22;2019:8970645. doi: 10.1155/2019/8970645. eCollection 2019.

24.

The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).

Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn-Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Oing C, Bokemeyer C.

Urol Oncol. 2019 Nov;37(11):809.e19-809.e25. doi: 10.1016/j.urolonc.2019.07.020. Epub 2019 Sep 5.

PMID:
31494007
25.

The P2-receptor-mediated Ca2+ signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension.

Hennigs JK, Lüneburg N, Stage A, Schmitz M, Körbelin J, Harbaum L, Matuszcak C, Mienert J, Bokemeyer C, Böger RH, Kiefmann R, Klose H.

Purinergic Signal. 2019 Sep;15(3):299-311. doi: 10.1007/s11302-019-09674-1. Epub 2019 Aug 8.

26.

New Trisulfated Steroids from the Vietnamese Marine Sponge Halichondria vansoesti and Their PSA Expression and Glucose Uptake Inhibitory Activities.

Tabakmakher KM, Makarieva TN, Denisenko VA, Popov RS, Dmitrenok PS, Dyshlovoy SA, Grebnev BB, Bokemeyer C, von Amsberg G, Cuong NX.

Mar Drugs. 2019 Jul 27;17(8). pii: E445. doi: 10.3390/md17080445.

27.
28.

[Monoclonal Gammopathy Of Unknown Significance - A Common Incidental Finding - What is to be thought of? What has to be done?]

Schieferdecker A, Binder M, Weisel K, Bokemeyer C.

Dtsch Med Wochenschr. 2019 Jul;144(14):982-989. doi: 10.1055/a-0832-3393. Epub 2019 Jul 16. Review. German.

PMID:
31311049
29.

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.

Janning M, Kobus F, Babayan A, Wikman H, Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Böttcher LM, Päsler S, Gorges TM, O'Flaherty L, Hille C, Joosse SA, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S.

Cancers (Basel). 2019 Jun 17;11(6). pii: E835. doi: 10.3390/cancers11060835.

30.

Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia.

Engel NW, Schliffke S, Schüller U, Frenzel C, Bokemeyer C, Kubisch C, Lessel D.

Front Oncol. 2019 May 22;9:420. doi: 10.3389/fonc.2019.00420. eCollection 2019.

31.

Impact of taste and smell training on taste disorders during chemotherapy - TASTE trial.

von Grundherr J, Koch B, Grimm D, Salchow J, Valentini L, Hummel T, Bokemeyer C, Stein A, Mann J.

Cancer Manag Res. 2019 May 16;11:4493-4504. doi: 10.2147/CMAR.S188903. eCollection 2019.

32.

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib.

Janjetovic S, Asemissen AM, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P.

Tumori. 2019 Dec;105(6):NP8-NP11. doi: 10.1177/0300891619839473. Epub 2019 Apr 1.

PMID:
30935343
33.

Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.

Oing C, Skowron MA, Bokemeyer C, Nettersheim D.

Andrology. 2019 Jul;7(4):487-497. doi: 10.1111/andr.12611. Epub 2019 Mar 29. Review.

PMID:
30924611
34.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G.

J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15.

PMID:
30875280
35.

Current pharmacotherapy for testicular germ cell cancer.

Alsdorf W, Seidel C, Bokemeyer C, Oing C.

Expert Opin Pharmacother. 2019 May;20(7):837-850. doi: 10.1080/14656566.2019.1583745. Epub 2019 Mar 8. Review.

PMID:
30849243
36.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.

Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K.

Future Oncol. 2019 Mar;15(8):897-907. doi: 10.2217/fon-2018-0814. Epub 2019 Mar 4.

37.

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.

Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M.

Mol Cancer Ther. 2019 Apr;18(4):823-833. doi: 10.1158/1535-7163.MCT-18-0849. Epub 2019 Mar 1.

38.

Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S.

Int J Cancer. 2019 Aug 1;145(3):857-868. doi: 10.1002/ijc.32163. Epub 2019 Mar 4.

PMID:
30694523
39.

5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells.

Oing C, Verem I, Mansour WY, Bokemeyer C, Dyshlovoy S, Honecker F.

Int J Mol Sci. 2018 Dec 21;20(1). pii: E21. doi: 10.3390/ijms20010021.

40.

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE.

Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7.

PMID:
30529901
41.

Apixaban for the Treatment of Chronic Disseminated Intravascular Coagulation: A Report of Two Cases.

Janjetovic S, Holstein K, Dicke C, Bokemeyer C, Langer F.

Hamostaseologie. 2019 Aug;39(3):294-297. doi: 10.1055/s-0038-1675386. Epub 2018 Nov 19.

PMID:
30453340
42.

Palliative treatment of germ cell cancer.

Oing C, Giannatempo P, Honecker F, Oechsle K, Bokemeyer C, Beyer J.

Cancer Treat Rev. 2018 Dec;71:102-107. doi: 10.1016/j.ctrv.2018.10.007. Epub 2018 Oct 22. Review.

43.

Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients.

Samsen A, von der Heyde S, Bokemeyer C, David KA, Flath B, Graap M, Grebenstein B, Heflik L, Hollburg W, Layer P, von Leitner E, Overkamp F, Saeger W, Schneider S, von Seydewitz CU, Stang A, Stein A, Zornig C, Juhl H.

Oncotarget. 2018 Oct 5;9(78):34794-34809. doi: 10.18632/oncotarget.26198. eCollection 2018 Oct 5.

44.

[Positron emission tomography in germ cell tumors in men : Possibilities and limitations].

Schriefer P, Hartmann M, Oechsle K, Meyer CP, Klutmann S, Fisch M, Bokemeyer C, Oing C.

Urologe A. 2019 Apr;58(4):418-423. doi: 10.1007/s00120-018-0797-x. Review. German.

PMID:
30374517
45.

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.

Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I.

Support Care Cancer. 2019 Jun;27(6):2301-2312. doi: 10.1007/s00520-018-4513-6. Epub 2018 Oct 20.

PMID:
30343410
46.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv271. doi: 10.1093/annonc/mdy323. No abstract available.

47.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL.

Eur J Cancer. 2018 Nov;103:205-213. doi: 10.1016/j.ejca.2018.08.020. Epub 2018 Sep 27.

48.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.

Ann Oncol. 2018 Oct;29 Suppl 4:iv96-iv110. doi: 10.1093/annonc/mdx758. Epub 2020 Jan 7. Review. No abstract available.

PMID:
32169245
49.

Corrections to "Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines".

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct;29 Suppl 4:iv271. doi: 10.1093/annonc/mdy323. Epub 2020 Jan 7. No abstract available.

PMID:
32169239
50.

The Impact of Bleeding Disorders on the Socioeconomic Status of Adult Patients.

Holstein K, von Mackensen S, Bokemeyer C, Langer F.

Hamostaseologie. 2018 Aug;38(3):150-157. doi: 10.5482/HAMO-16-12-0047. Epub 2018 Sep 27.

PMID:
30261520

Supplemental Content

Loading ...
Support Center